Type II diabetes is a chronic condition that results when the body's insulin does not work effectively; it affects up to 6 per cent of the US population, and has been growing in prevalence over the past decade. This issue covers all areas of non insulin-dependent diabetes including insulin therapy and insulin strategies, hypertension management, glycemic management, multifactorial management, dyslipidemia, and novel pharmacologic agents.
Reihe
Sprache
Verlagsort
Verlagsgruppe
Elsevier - Health Sciences Division
Zielgruppe
ISBN-13
978-1-4160-2686-0 (9781416026860)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Klassifikation
1. Early Insulin Therapy in Type 2 Diabetes: Exploring Insulin Cardioprotection and Beta Cell Preservation (Gerstein and Rosenstock) 2. Type 2 Diabetes: A Pandemic Disease (Harris) 3. The Insulin Resistance Syndrome: One Disease, Multiple Consequences (Reaven) 4. Dual Defects in the Disease Continuum of Type 2 Diabetes: Insulin Resistance and Beta Cell Deficiency (Kahn) 5. Type 2 Diabetes as a Cardiovascular Equivalent (Haffner) 6. Dyslipidemia Management in Type 2 Diabetes and the ATP III (Goldberg) 7. Hypertension Management in Type 2 Diabetes and the JNC VII (Sowers) 8. Glycolic Management in Type 2 Diabetes: Emerging Strategies with Oral Combination Agents (Riddle) 9. Multifactor Management in Type 2 Diabetes (Kendall) 10. Potential Cardioprotective Effects of Insulin Sensitizers (Fonseca) 11. Insulin Strategies in the Hospital Setting and the CCU (Moghissi and Hirsch) 12. Novel Pharmacologic Agents for Type 2 Diabetes (Ratner) 13. Preventing Type 2 Diabetes: How Far Have We Gone and What Else Do We Need? (Sherwin) 14. Prevention of Cardiovascular Outcomes in Type 2 Diabetes: Trials in the Horizon (Buse) 15. Emerging Evidence-Based Outcomes from Cholesterol and Hypertension Prevention Trials: Cardiovascular Events in Type 2 Diabetes (Nissen)
